jon krebs (@fishingjon51) profile picture

Huge outdoorman, love to fish, hunt,and golf in KY - and pull for my louisville cards

Joined March 2014
$IBRX Goldman Sachs increased its ImmunityBio position by 27.69% in Q3, adding nearly 896,000 shares. As of September 30, 2026, Goldman held 4,129,906 shares, compared with 3,234,277 in the previous filing. That’s a meaningful increase in institutional exposure. Goldman is building its position, and that’s worth paying attention to. 👀📈
4
8
105
3,333
jon krebs retweeted
$IBRX Those who deal with money have spoken and that is huge!
ImmunityBio ranked No. 2 on the 2026 @Deloitte Technology Fast 500™, reflecting revenue growth of more than 47,000% from 2022 to 2025. Thank you to our employees and partners for their contributions to this milestone. Read the full announcement: immunitybio.com/immunitybio-… $IBRX #fast500
2
18
152
3,544
A new soccer club has formed in Oldham County. Oldham FC. Could be a game changer as they compete in the N1 league. Give them a follow and check it out instagram.com/oldham.fc?cplk…
1
5
14
3,959
The official list of performance fees paid by Woodstock in August 1969, a document that came to light years later. Jimi Hendrix topped the list with $18,000, closing the festival as the main headliner, which is equivalent to about $150,000 today when adjusted for inflation.
375
1,076
132
5,935
686,115
Come on out! Free admission
3
9
840
jon krebs retweeted
🚨 $IBRX: CATALYST ROADMAP — NOV 2026 TO MAR 2027 (as of 11/10/26) ANKTIVA (N-803) is an IL-15 superagonist — activates NK + CD8 T cells, helps reverse lymphopenia. Beyond bladder cancer. 🔵 NOVEMBER — CLINICAL NEWS & INVESTOR CONFERENCES QUILT-2.005: ANKTIVA + BCG met primary endpoint vs BCG alone in BCG-naïve bladder cancer. Statistically significant improvement in CIS ± papillary. Detailed data at upcoming congress. sBLA target: year-end 2026. Why it matters: BCG-naïve = larger first-line population. QUILT-3.032 (J Urol, N=100): 84% cystectomy avoidance at 36 mo among responders, median CR 26.6 mo, some >53 mo. Conferences: SNO Nov 12-15 Philadelphia, UBS Nov 16-17 London, Jefferies Nov 16-19 London, MaTOS Lung Nov 19-22 Half Moon Bay. Mgmt presentations at UBS + Jefferies Nov 16. 🟢 DECEMBER - THREE POTENTIAL CATALYSTS 1. REGULATORY
BCG-naïve sBLA submission target in Q4 2026. 2. CLINICAL
Further QUILT-2.005 data and medical-congress presentation watch. 3. COMMERCIAL
International expansion, European access and continued market development. Industry conferences to watch:
• Piper Sandler: Dec. 1–3
• ESMO Asia: Dec. 4–6
• ASH Annual Meeting: Dec. 12–15 These are industry conference dates; ImmunityBio participation is not confirmed for all three. 🟣 JANUARY — SEPSIS PHASE 2: CLINICAL-PROGRESS WATCH Two separate studies evaluating ANKTIVA alongside standard of care, without BCG. The studies focus on critically ill adults with sepsis and persistent lymphopenia. Key areas to watch:
• Trial-site activation and activity.
• Enrollment updates.
• Safety information.
• U.S. and European development strategy.
• 28-day all-cause mortality. This is a clinical-progress watch—not a promised recruitment or results date. Clinical benefit in sepsis has not been established. 🟢 FEBRUARY — REGULATORY & COMMERCIAL WATCH • Potential FDA acceptance of the BCG-naïve sBLA, if submitted in Q4 and accepted. 
• Continued international expansion and commercial progress. 
• Annual Report / Form 10-K filing watch. The exact 2027 filing date is not confirmed. 🔵 MARCH — EARNINGS & LONG COVID • Q4 / FY 2026 earnings watch — approximately March 2, 2027, based on a third-party estimate, not a confirmed company date. 
• Long COVID Phase 2, NCT07123727 — estimated primary completion March 2027. Registry timing is not a guaranteed data-release date. 🌍 THE COMMERCIAL FOUNDATION • $48.7M Q3 net product revenue, up 53% year over year. 
• $143.6M first-nine-month net product revenue, up 92% year over year. 
• ANKTIVA authorized in 35 countries. 
• Israel became the 35th country through the Rafa Laboratories partnership. 
• First European patients treated. 
• $334.3M in cash, cash equivalents and marketable securities as of September 30, 2026. 🧬 THE BIGGER IL-15 PLATFORM STORY The opportunity extends beyond bladder cancer: • Papillary-only bladder cancer: FDA label expansion approved October 14. 
• Lung cancer: Saudi conditional accelerated approval in metastatic NSCLC with checkpoint therapy. 
• Lymphopenia: FDA-authorized expanded access program. 
• Pancreatic cancer: ANKTIVA + CAR-NK program with RMAT designation. 
• Glioblastoma: Phase 2 completed; registrational development planned. 
• Sepsis: Two separate clinical studies. 
• HIV and Long COVID: Additional areas of investigation. Also watch for: BioShield and the company’s broader manufacturing and platform strategy. 📈 WHY THE NEXT FEW MONTHS MATTER This is the bigger story: 1 Clinical evidence is expanding 2 Regulatory opportunities are developing 3 International access is becoming tangible 4 Commercial revenue is growing 5 The IL-15 platform is being investigated across additional diseases $IBRX DOESN’T HAVE TO WAIT FOR EARNINGS TO HAVE IMPORTANT NEWS $IBRX @ImmunityBio @DrPatrick #IBRX #ANKTIVA #IL15 #Immunotherapy #Biotech #CancerResearch #Sepsis Info as of Nov 11 2026. Dates are estimates
🤖 Made with AI
2
8
1
37
2,561
jon krebs retweeted
I see miracle ivermectin cures everywhere. "Nothing else worked." "Doctors are hiding it." So I went through every human study I could find. The biggest "real-world" study was pulled a month ago. Here's what's real and what's hype.
24
16
2
90
20,666
jon krebs retweeted
This dip on $IBRX is a buying opportunity of a lifetime that will never come back. The QUILT-2.005 head-to-head RCT win completely de-risks ImmunityBio’s IL-15 platform, turning Anktiva into a blockbuster primed to capture several massive global markets: • Lung Cancer (NSCLC): Targets a $30B+ market with accelerated Phase 3 pathways. • Glioblastoma (GBM): Targets an underserved frontier backed by a 100% disease control rate. • Pancreatic Cancer: Targets a market scaling past $8B with FDA Breakthrough designations. By proving the platform works against active comparators, $IBRX is ready to scale across indications and vault its long-term valuation into the stratosphere. DYOR @LoriMills4CA42 @DrPatrick
8
5
138
4,002
It takes courage to reveal what many of us know. Sophisticated corruption affects millions of lives. Big pharma should not be allowed to direct the future of health care to protect their business interests and prevent access to innovative therapies. I urge all to listen to Calley’s podcast with Joe Rogan. @calleymeans
89
394
27
1,922
178,002
jon krebs retweeted
$IBRX Friends and fellow investors this is an updated version including the conclusion on Glioblastoma at the ESMO meeting in Madrid. Q3 Earnings Report and Updates, growing revenue. The average analyst target is still around $14.25. With the elevated short interest any catalyst update will translate into a higher stock price (short squeeze). Large list of catalysts, Lymphopenia (approval Q4 2026), HIV & Sepsis. Glioblastoma, Prostate, Pancreatic, Head & Neck, Colon, Liver, Ovarian, Lung, Indolent non-Hodgkin and Waldenström micro bulimia. Accelerated approval for Sepsis. Glioblastoma 19 out of 23 patients remain alive. Approval of GBM Q2 2027. At the recent ESMO (European Society for Medical Oncology) conference in Madrid (10.23 / 27) as per Dr. Simon Khagi's report the findings support that reconstituting lymphocytes contributes to the disease control in rGBM. The first report in disease control in participants with rGBM who received orchestrated systemic immunotherapy with an L-15 receptor agonist and CAR-NK cells combined with BEV.Ph2b efficacy data will be reported after a median follow up time of 6 months has been reached. ANKTIVA in combination with BCG / Papillary NMIBC label expansion. This will be reflected a lot in the Q4 earning report. Lymphopenia and Pancreatic Cancer with RMAT designations since 02.2025. Global Expansion, 34 countries. EU Germany first patient treated with ANKTIVA & BCG. Former World Bank President Dr. Jim Yong Kim is the Vice Chairman to lead global expansion. Leonardo set up artificial intelligence robotic mass production de MK cells. Start of Sepsis with Nant Leonardo. Hiring professionals at the Dunkirk plant. 400 vials per minute. Creating a World Bank of NK cells and T cells are collected, engineered and infused back into the patient. Lynch Syndrome (Cancer Prevention Vaccine). RMAT designation for M-ceNK. Approval of Japanese BCG. Next generation of CAR-T therapy for Leukemias. Chemotherapy and radiation free oncology, in most cases no hospitalization is needed. ANKTIVA will improve aging and longevity. Local barriers remain between patients and the treatments they desperately need. Keep your shares and buy more!
2
5
2
101
3,718
jon krebs retweeted
$IBRX Another major door just opened for Anktiva! Job well done, team @ImmunityBio
We're thrilled to share a major milestone: the first patients in Europe have been treated with ANKTIVA® + BCG for BCG-unresponsive NMIBC with CIS, beginning in Germany & Austria, following the EC's February 2026 conditional authorization. With support from partners Accord Healthcare and Uniphar, we're working to expand access for eligible patients across Europe. Full press release & Important Safety Information: immunitybio.com/immunitybio-…
3
72
1,330
4:30 on a Wednesday for a state semifinal is nuts.
Wednesday's KHSAA boys soccer state semifinals are set for Paul Dunbar. (Yep, Paul Dunbar gets to play on its home field.) 4:30 p.m. - #1 St. Xavier vs. #6 Bardstown 8 p.m. - #3 Paul Dunbar vs. #5 Ryle
2
2
31
6,537
Ran out of ink scratching horses Trainer buddy “14 goons running around trying to justify them being here “
6
4
1
50
4,986
How excited are Brewers fans right now? This is American Family Field in Milwaukee. The game is being played in Tampa.
128
666
75
7,445
180,560
jon krebs retweeted
MY HOT NEIGHBOR 🤤🥵 I was dancing in the corridor like nobody was watching when a deep voice interrupted me. “Should I come back when the concert is over?” I froze. My new neighbor stood in his doorway, holding a black mug, looking far too handsome for someone who had just caught me embarrassing myself. “I wasn’t dancing for you,” I said quickly. He smiled. “That’s unfortunate. You seem exactly like my type.” Then he walked away. I immediately called my best friend. “Nessa, my new neighbor is dangerously hot. I might be in trouble.” And the worst part? I already wanted to see him again.....
6
88
106
7,724
Which colleges have generated the most in MLB Draft signing bonuses from 2015–2026? 💰 LSU leads the way, with players drafted out of the program earning a combined $83.8 million in signing bonuses over the last 11 years.
3
28
11
226
60,177
jon krebs retweeted
"All four years, we wanted to make it to state & beat our rival (Sacred Heart), so it’s a really big thing for the whole team, & we’re really proud of it.” Led by Whitney Cooper, Assumption beat CAL for its first 7th Region girls soccer title since 2022 courier-journal.com/story/sp…
4
13
3,606
Replying to @CardChronicle
All started here! About to bring championship #2 to this city! Go Giants!
1
8
1
113
8,434
4 in the Top 10. 8 in the Top 20 🔥 #GoCards
7
57
3
270
7,887